BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia

Current Opinion in Investigational Drugs

Volumn 11, Issue 1, 2010, Pages 92-100

  Fitzgerald, Paul B ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BL 1020; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; MK 0777; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

AKATHISIA; ANXIETY; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR DISEASE; CATALEPSY; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GABAERGIC SYSTEM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERACTIVITY; HYPERPROLACTINEMIA; INSOMNIA; LEUKOCYTE COUNT; MENTAL DISEASE; MUSCLE SPASM; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PHARMACODYNAMICS; POLYURIA; RECEPTOR OCCUPANCY; REVIEW; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TARDIVE DYSKINESIA; TIC; TOXICITY TESTING; TREATMENT RESPONSE; TREMOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DOPAMINE; DRUG EVALUATION, PRECLINICAL; GAMMA-AMINOBUTYRIC ACID; HUMANS; PATENTS AS TOPIC; PERPHENAZINE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, GABA-A; SCHIZOPHRENIA;

EID: 74549125415     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Treatment-resistant schizophrenia - The role of clozapine. Meltzer HY CURR MED RES OPIN 1997 14 1 1-20
2. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Kapur S, Seeman P AM J PSYCHIATRY 2001 158 3 360-369
3. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. Kapur S, Seeman P J PSYCHIATRY NEUROSCI 2000 25 2 161-166
4. The positive and negative syndrome scale (PANSS) for schizophrenia. Kay SR, Fiszbein A, Opler LA SCHIZOPHR BULL 1987 13 2 261-276.
5. A new benzodiazepine pharmacology. Mohler H, Fritschy JM, Rudolph U J PHARMACOL EXP THER 2002 300 1 2-8
6. BioLineRx in-licenses innovative platform for the treatment of neurological disorders from Tel Aviv and Bar Ilan Universities. BioLineRx Ltd PRESS RELEASE 2004 May 06
7. The World Health Report 2004 - Changing history. World Health Organization WHO: WORLD HEALTH REP 2004 May 31
8. BioLineRx awarded Israeli Government grant of $21 million for the development of innovative pre-clinical drug candidates. BioLineRx Ltd PRESS RELEASE 2004 December 02
9. BioLineRx successfully completes phase 1 clinical trials of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia. BioLineRx Ltd PRESS RELEASE 2007 February 13
10. BioLineRx initiates phase II trial of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia. BioLineRx Ltd PRESS RELEASE 2007 July 25
11. A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. Nudelman A, Gil-Ad I, Shpaisman N, Terasenko I, Ron H, Savitsky K, Geffen Y, Weizman A, Rephaeli A J MED CHEM 2008 51 9 2858-2862
12. BioLineRx initiates phase 2b clinical trials of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia. BioLineRx Ltd PRESS RELEASE 2008 June 12
13. An open study of the safety and efficacy of a novel antipsychotic (BL-1020) with reduced risk for extrapyramidal symptoms. Anand R, Davidson M, Geffen Y, Vasile D, Dan I EUR NEUROPSYCHOPHARMACOL 2008 18 Suppl 4 Abs P.3.c.037
14. BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. Geffen Y, Nudelman A, Gil-Ad I, Rephaeli A, Huang M, Savitsky K, Klapper L, Ilan W, Meltzer HY, Weizman A EUR NEUROPSYCHOPHARMACOL 2009 19 1 1-13
15. First in class GABA enhanced antipsychotic: Results of phase 1, double blind placebo controlled study. Davidson M, Geffen Y, Weizman A BIOL PSYCHIATRY 2007 61 8 Abs 260
16. A novel class of antipsychotic for the treatment of schizophrenia. Geffen Y, Weizman A, Gil-Ad I, Nudelman A, Rephaeli A BIOL PSYCHIATRY 2006 59 8 Abs 862
17. A novel class of antipsychotic for the treatment of schizophrenia. Geffen Y, Gil-Ad I, Nudelm A, Rephaeli A, Weizman A INT J NEUROPSYCHOPHARMACOL 2006 9 Suppl 1 Abs P01.153
18. Novel antipsychotic with dopamine antagonism and GABAergic activity. Halachmi S, Nudelman A, Rephaeli A, Gil-Ad I, Weizman A BEHAV PHARMACOL 2005 16 Suppl 1 Abs A83.
19. BL-1020 a new antipsychotic with GABA agonist activity. Davidson M, Geffen Y, Appel L, Kapur S BIOL PSYCHIATRY 2008 63 7 Suppl S Abs 484
20. BL1020 improves a subchronic phencyclidine-induced deficit in object recognition memory in the rat: Potentially via enhanced dopamine release in the prefrontal cortex. Neill JC, Idris N, Grayson B, Tabakman R, Naftali E, Jencmen S, Geffen Y BIOL PSYCHIATRY 2009 65 8 Abs 248
21. BioLineRx announces positive topline results for BL-1020, a first in class GABA enhanced antipsychotic for the treatment of schizophrenia. BioLineRx Ltd PRESS RELEASE 2009 September 14
22. EAGLE trial signals breakthrough in the treatment of schizophrenia BioLineRx's BL-1020 significantly improves cognitive function in patients with schizophrenia. BioLineRx Ltd PRESS RELEASE 2009 September 24
23. GABAA receptor subtype-selective drugs - Where are we now? Atack JR SOC NEUROSCI ANN MEET 2009 39 Abs 114.2
24. First in class GABA enhanced antipsychotic for schizophrenia: Results of phase IIa in schizophrenic patients. Geffen Y, Appel L, Kapur S, Davidson M SCHIZOPHR RES 2008 1-3 Suppl 2 Abs 581
25. BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. Appel L, Geffen Y, Heurling K, Eriksson C, Antoni G, Kapur S EUR NEUROPSYCHOPHARMACOL 2009 doi:10.1016/j.euroneuro.2009.07. 009
26. Prevalence studies in schizophrenia. Torrey EF BR J PSYCHIATRY 1987 150 598-608
27. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S CURR PHARM DESIGN 2009 15 22 2550-2559
28. What CATIE found: Results from the schizophrenia trial. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, Hsiao JK, Lieberman JA PSYC SERVICES 2008 59 5 500-506
29. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Bhoopathi PS, Soares-Weiser K COCHRANE DATABASE SYST REV 2006 3 CD000205.
30. Benzodiazepines in schizophrenia. Stimmel GL PHARMACOTHERAPY 1996 16 6 Pt 2 S148-S151
31. Diazepam treatment of early symptoms of schizophrenic relapse. Kirkpatrick B, Buchanan RW, Waltrip RW, Jauch D, Carpenter WT J NERV MENT DIS 1989 177 1 52-53
32. Imidazenil: A new partial positive allosteric modulator of β-aminobutyric acid (GABA) action at GABAA receptors. Giusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A, Costa E J PHARMACOL EXP THER 1993 266 2 1018-1028
33. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, Montrose D AM J PSYCHIATRY 2008 165 12 1585-1593
34. Schizophrenia, 'just the facts' 4. Clinical features and conceptualization. Tandon R, Nasrallah HA, Keshavan MS. SCHIZOPHR RES 2009 110 1-3 1-23.
35. Schizophrenia. Mueser KT, McGurk SR LANCET 2004 363 9426 2063-2072
36. Schizophrenia: A concise overview of incidence, prevalence, and mortality. McGrath J, Saha S, Chant D, Welham J EPIDEMIOL REV 2008 30 1 67-76
37. Long-term outcome of patients with schizophrenia: A review. Jobe TH, Harrow M CAN J PSYCHIATRY 2005 50 14 892-900
38. A new framework for investigating antipsychotic action in humans: Lessons from PET imaging. Kapur S MOL PSYCHIATRY 1998 3 2 135-140
39. Extrapyramidal side-effects of clozapine and haloperidol. Kurz M, Hummer M, Oberbauer H, Fleischhacker WW PSYCHOPHARMACOLOGY 1995 118 1 52-56
40. Atypical antipsychotics: Mechanism of action. Seeman P CAN J PSYCHIATRY 2002 47 1 27-38
41. Theoretical insights into the mechanism of action of atypical antipsychotics. Tort ABL, Souza DO, Lara DR PROG NEURO PSYCHOPHARMACOL BIOL PSYCHIATRY 2006 30 4 541-548.
42. Antipsychotic treatment in schizophrenia: Atypical options and NICE guidance. Mortimer AM EUR PSYCHIATRY 2003 18 5 209-219
43. Treatment-resistant schizophrenia. Elkis H PSYCHIATR CLIN N AM 2007 30 3 511-533
44. Clozapine, GABAB, and the treatment of resistant schizophrenia. Daskalakis ZJ, George TP CLIN PHARMACOL THER 2009 86 4 442-446
45. Clozapine: A clinical review of adverse effects and management. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM ANN CLIN PSYCHIATY 2003 15 1 33-48
46. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Murphy BP, Chung YC, Park TW, McGorry PD SCHIZOPHR RES 2006 88 1-3 5-25
47. Pharmacological treatment of negative symptoms of schizophrenia: Therapeutic opportunity or cul-de-sac? Buckley PF, Stahl SM ACTA PSYCHIATR SCAND 2007 115 2 93-100
48. Prefrontal cortex, negative symptoms, and schizophrenia: An MRI study. Wible CG, Anderson J, Shenton ME, Kricun A, Hirayasu Y, Tanaka S, Levitt JJ, O'Donnell BF, Kikinis R, Jolesz FA, McCarley RW PSYCHIATRY RES NEUROIMAGING 2001 108 2 65-78
49. Negative symptoms in schizophrenia - A review. Makinen J, Miettunen J, Isohanni M, Koponen H NORD J PSYCHIATRY 2008 62 5 334-341
50. Negative symptoms of schizophrenia: A problem that will not go away. Stahl SM, Buckley PF ACTA PSYCHIATR SCAND 2007 115 1 4-11
51. Deciphering the disease process of schizophrenia: The contribution of cortical GABA neurons. Lewis DA, Hashimoto T INT REV NEUROBIOL 2007 78 109-131
52. Cortical inhibitory neurons and schizophrenia. Lewis DA, Hashimoto T, Volk DW NAT REV NEUROSCI 2005 6 4 312-324.
53. Gene-expression for glutamic-acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jones EG ARCH GEN PSYCHIATRY 1995 52 4 258-266
54. Amygdalar activation alters the hippocampal GABA system: "Partial" modelling for postmortem changes in schizophrenia. Berretta S, Munno DW, Benes FM J COMP NEUROL 2001 431 2 129-138
55. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA CEREB CORTEX 2002 12 10 1063-1070
56. Blood-brain barrier to H-3-β-aminobutyric acid in normal and amino oxyacetic acid-treated animals. KURIYAMA K, SZE PY NEUROPHARMACOLOGY 1971 10 1 103-108
57. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)- 6-(2-ethyl-2H-1,2,4-triazol-3- ylmethoxy)-3-(2-fluorophenyl)- 1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates and man. Atack J, Wong D, Fryer T, Ryan C, Sanabria S, Zhou Y, Dannals R, Eng WS, Gibson R, Burns D, Vega J et al J PHARMACOL EXP THER 2009 doi:10.1124/jpet.109.157909
58. GABA and schizophrenia: A review of basic science and clinical studies. Wassef A, Baker J, Kochan LD J CLIN PSYCHOPHARMACOL 2003 23 6 601-640
59. A GABAergic cortical deficit dominates schizophrenia pathophysiology. Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L, Veldic M CRIT REV NEUROBIOL 2004 16 1-2 1-23